A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)
Latest Information Update: 31 May 2022
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Acronyms EVALUATE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 12 May 2022 Results assessing the association between changes in these markers with changes in cardiac structure, function and health status, published in the European Journal of Heart Failure
- 30 Mar 2020 Results (n=15,038) of meta-analysis exploring angioedema in the 6 clinical trials (PARADIGM-HF, PIONEER, TITRATION, EVALUATE-HF & PARAGON-HF) and in real-world pharmacovigilance data, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
- 18 Nov 2019 Results assessing effect of Sacubitril/valsartan treatment on pulmonary artery systolic pressure presented at the American Heart Association Scientific Sessions 2019